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Background: Glycated hemoglobin A1c (HbA1c) has been used as an index of glycemic control in the
management, guidance, and clinical trials of diabetic patients for the past 35 years. The aim of this study was to
validate the HbA1c model in patients with type 1 and type 2 diabetes and to use it to support interpretation of
HbA1c in different clinical situations.
Methods: The HbA1c model was identified in 30 patients (15 with type 1 diabetes and 15 with type 2 diabetes) by
estimating the overall glycation rate constant (k), based on results of continuous glucose monitoring. The model
was validated by assessing its ability to predict HbA1c changes in cultures of erythrocytes in vitro and to reproduce
results of the A1C-Derived Average Glucose (ADAG) study. The model was used to simulate the influence of
different glucose profiles on HbA1c.
Results: The mean k was equal to 1.296 ± 0.216 × 10−9 l mmol−1 s−1 with no difference between type 1 and type 2
diabetes. The mean coefficient of variation of k was equal to 16.7%. The model predicted HbA1c levels in vitro with a
mean absolute difference less than 0.3% (3.3 mmol/mol). It reproduced the linear relationship of HbA1c and mean
glucose levels established in the ADAG study. The simulation experiments demonstrated that during periods of
unstable glycemic control, glycemic profiles with the same mean glucose might result in much different HbA1c levels.
Conclusions: Patients with type 1 and type 2 diabetes are characterized by the same mean value of k, but there is
considerable interindividual variation in the relationship of HbA1c and mean glucose level. Results suggest that
reciprocal changes in glycation rate and the life span of erythrocytes exist in a wide range of HbA1c values. Thus, for an
average patient with diabetes, no modifications of parameters of the glycation model are required to obtain
meaningful HbA1c predictions. Interpreting HbA1c as a measure of the mean glucose is fully justified only in the case of
stable glycemia. The model and more frequent tests of HbA1c might be used to decrease ambiguity of interpreting
HbA1c in terms of glycemic control.
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Glycated hemoglobin A1c (HbA1c) has been used as an
index of glycemic control in the management, clinical
guidance, and clinical trials of diabetic patients for the
past 35 years. In 2009, HbA1c became a diagnostic test
for diabetes [1]. In 2008, the multi-center A1C-Derived
Average Glucose (ADAG) study was concluded, docu-
menting the linear relationship between HbA1c and
mean blood glucose (MBG) [2]. For an average individ-
ual, this relationship can be used to report HbA1c as an
estimated average glucose level over a period of 3 to
4 months (which is considered to be an approximate life
span of erythrocytes) preceding HbA1c test execution.
According to the ADAG study assumptions, such an
estimate should fall within ±15% of the study-wide calcu-
lated level for 90% of the individual patients [2]. However,
this average linear relationship cannot be combined with
any additional knowledge about the particular patient
(e.g., results of HbA1c tests repeated within a short time
period or information from a patient that she or he expe-
rienced a substantial improvement in glycemic control a
few weeks ago) to narrow this 15% uncertainty range.
Neither can it be used to study the influence of different
glycemia profiles on the HbA1c level. For this purpose,
mathematical modeling has been applied, among other
methodologies [3-12].
In 2011, Ladyzynski et al. demonstrated that it was
feasible to approximate the average relationship of
HbA1c and glycemia reported in the ADAG study using
one of such models [12]. The kinetics of hemoglobin
glycation in this model can be characterized by an over-
all hemoglobin glycation rate constant (k). Besides the
kinetics of the hemoglobin glycation reaction, the release
of erythrocytes to the blood stream from the bone mar-
row and the elimination of erythrocytes from circulation
were taken into account while calculating the average
HbA1c level over all equal-aged cohorts of erythrocytes
circulating in the vascular system at any given time.
Because the above-mentioned report [12] was based
on data from healthy volunteers, it seemed advisable to
validate the model using data from patients with dia-
betes. We expected the mean values of k to be similar in
patients with type 1 and type 2 diabetes. However, we
have not found any data in the literature confirming
such an equality of the glycation rate constants in these
two groups of patients. In reports available in the litera-
ture, the total number of cases studied so far in patients
with diabetes is limited, making it difficult to draw con-
clusions about the mean values and the intersubject vari-
ability of k in type 1 and type 2 diabetes. Contrarily,
many clinical studies reported high variability of HbA1c,
which could hardly be explained by differences in gly-
cemic control. Taking into consideration the different
pathophysiology of type 1 and type 2 diabetes andconsidering all the factors other than glycemia that might
influence the glycation rate (e.g., pH, oxidative stress, en-
zymatic deglycation, Schiff base inhibitors), the possibility
that there are significant differences in formation of HbA1c
in these two groups of patients cannot be ruled out.
The aim of the current work was threefold: (1) to esti-
mate and compare the mean k and its interindividual
variability in patients with type 1 and type 2 diabetes,
(2) to validate the ability of the mathematical model to
predict HbA1c concentration based on different glucose
levels and to reproduce the relationship of HbA1c and
glycemia established in the ADAG study, and (3) to
simulate different glycemia profiles and their influence
on the HbA1c concentration and to use these simula-
tions to support interpretation of HbA1c in different
clinical situations.
Methods
In the first part of the study, an experimental procedure
described in detail elsewhere [7,12] was used to estimate
k and to evaluate the HbA1c model. The procedure con-
sisted of four phases, described below.
Blood glucose and HbA1c estimation in vivo
Glycemia course over a 120-day period was estimated
based on CGM using a Guardian RT system (Medtronic
Diabetes, Northridge, CA, USA) calibrated at least 4 times
a day using capillary glucose measured with an Accu-Chek
Go glucometer (Roche Diagnostics, Basel, Switzerland).
Glucose concentrations measured with glucometers were
rescaled to reflect the whole blood glucose concentrations
as if they had been measured with the gold standard glu-
cose analyzer YSI 2300 Stat Plus (Yellow Springs Instru-
ments Inc., Yellow Springs, OH, USA) according to the
linear regression reported by Cohen et al. [13]. Then the
results were multiplied by 1.11, as recommended by the
International Federation of Clinical Chemistry and Labora-
tory Medicine (IFCC) [14], to reflect blood glucose (BG)
concentrations in plasma. Based on the DirectNet study, it
was assumed that Guardian RT neither underestimates nor
overestimates glucose concentration in relation to the cali-
brating results [15]. In each participant, 3 glucose sensors
were applied for 6 days, with an assumed time span of 4
and 2 weeks between application of the first two and the
last two sensors, respectively.
Two methods were used to estimate 120-day glycemia
profiles. In the first method, we calculated two separate
daily glycemia profiles representing working days and
weekends by a point-wise averaging of the daily recordings
(WW method). Then we connected these profiles repeat-
edly to obtain the extrapolated 120-day course. In the
second method, the rescaled-to-plasma daily profiles were
repeatedly copied to build the whole 120-day course,
without any intermediate averaging (ID method). Both
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value for each subject and to evaluate the sensitivity of
this estimate on the short-term glycemia variability.
The k value was also calculated based on an analytical
solution of the model under the assumption that BG
was equal to the mean value (MBG) for 120 days.
The HbA1c was measured at the end of usage of the last
sensor (5 repetitions were done) by applying the cation-
exchange HPLC method with a D-10 analyzer (Bio-Rad
Laboratories, Hercules, CA, USA). This analyzer mea-
sures HbA1c according to the National Glycohemoglo-
bin Standardization Programme (NGSP) as a percentage
of the total hemoglobin [16].
Cultivation of erythrocytes in vitro
At the end of glucose monitoring, 30 ml of blood was
sampled for cultivation of erythrocytes. The erythrocytes
isolated from the blood samples were cultured for up to
5 weeks at 37°C [7,12]. Three glucose levels were
maintained in culturing media corresponding to BG of
5.2 mmol/l, 10.5 mmol/l, and 15.7 mmol/l, respectively.
Glucose concentrations measured in the medium using
the YSI analyzer were divided by 1.06 to account for differ-
ent water content in the plasma and in the medium [14].
The following procedure was used every day to sustain
the presumed constant concentrations of glucose. First,
a sample of the medium was taken to measure the glu-
cose concentration before the old medium was replaced
by the fresh one. Second, the hemolized erythrocytes
were removed together with the old medium from a
cell-culture dish, and then the fresh medium containing
the desirable glucose concentration was added into the
culture. The difference between the glucose concentra-
tion at the beginning and at the end of each day was
decreasing with time because the number of viable
erythrocytes that were able to metabolize glucose was
also decreasing. Therefore, the glucose concentration in
each culture was not constant but instead was changing,
in a sawtooth-like manner, each day. To minimize errors
that were made during HbA1c modeling, we interpolated
these intraday changes of glucose concentration and
used the interpolated values in the model.
A series of preliminary experiments with different glu-
cose concentrations in the medium [7] confirmed that
after 14 days of culturing, the molality of glucose in the
medium and in the erythrocytes was the same (standard
deviation of the absolute relative differences was equal
to 3.6%). Glucose content in erythrocytes was not mea-
sured after the 14th day of culturing because of a limited
volume of samples. Thus, it cannot be ruled out that
glucose transport through the walls of the erythrocytes
may be affected in vitro as a result of changes in the
availability of GLUT1, which enable the facilitated diffu-
sion of glucose. However, the influence of such changeson the results must have been limited in the current
study because the constant levels of glucose were main-
tained in the medium.
We also sampled the cultures to measure HbA1c and
to estimate the number of viable erythrocytes using
Bürker’s chamber [17]. Samples for HbA1c testing were
frozen at −80°C until erythrocyte cultivation ended, and
then HbA1c was assessed in all samples. To ensure the via-
bility of erythrocytes in vitro (or our ability to properly re-
move nonviable cells and to detect viable cells), in the
preliminary tests we used two methods in parallel to esti-
mate the number of the viable cells in the cultures: a
microscopic method with Bürker’s chamber and a cyto-
metric method applying the Annexin V binding protocol.
In the preliminary tests, described above [7], we con-
ducted six in vitro experiments using blood samples from
the healthy volunteers. The apoptotic cells were detected
(in 5 samples in each experiment) using a FACSCalibur
cytometer and CellQuest software (Becton Dickinson,
San Diego, CA, USA).
We found a good agreement between the results of the
cytometric and the microscopic analyses. The mean differ-
ence of the viable erythrocytes count expressed in relation
to the erythrocytes’ count at the day of blood sampling for
the in vitro experiments between the microscopic and the
cytometric methods equaled 1.7 ± 2.8% (mean ± SD),
p < 0.002 [7]. This result confirmed that we were able to
properly distinguish the apoptotic cells from the viable
cells. Thus, we used the microscopic method in the main
cycle of experiments.
Estimation of the overall glycation rate constant
The applied HbA1c model assumes that HbA1c level de-
pends on three main processes: the kinetics of hemoglobin
glycation, the release of the reticulocytes from bone mar-
row and the elimination of erythrocytes from circulation.
The kinetics of hemoglobin glycation in the equal-aged




¼ −k  HbA  BG
where HbA denotes concentration of non-glycated
hemoglobin and t is time.
The most important assumptions of the model are as
follows: (1) the life span of erythrocytes is constant and
equal to 120 days, (2) the turnover of erythrocytes is con-
stant, (3) HbA1c concentration in the newly generated re-
ticulocytes is equal to zero [4,18], (4) erythrocytes are
eliminated in chronological order (“the oldest” ones are
eliminated first) [7], and (5) the influence of the spleen-
facilitated vesiculation on HbA1c is negligible [7,10]. The
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was assessed earlier [7].
Based on these assumptions, a hemoglobin mass bal-
ance equation was utilized to calculate HbA1c level in
the equal-aged cohort of erythrocytes at any particular
point in time, depending on BG. These calculations were
performed in parallel in 120 cohorts of erythrocytes of
different ages (ranging from 1 day to 120 days), and then
the results were averaged over all the cohorts to obtain
the modeled HbA1c level that corresponds to the mea-
sured HbA1c level. To estimate a value of k, calculations
were repeated with iteratively modified k until the abso-
lute difference between the calculated and the measured
HbA1c dropped below 0.046% (0.05 mmol/mol). To avoid
overestimation of k, the calculations were performed using
the unbiased IFCC-aligned HbA1c levels that were ob-
tained from the NGSP-aligned ones according to the
linear equation recommended by the IFCC [16]. In this
manuscript, HbA1c concentrations are reported according
to both scales, with the NGSP-aligned values expressed in
percentages of the total hemoglobin (%), followed by the
IFCC-aligned values in millimoles of HbA1c per mol of
the total hemoglobin (mmol/mol) given in parentheses.
The HbA1c model has been described in detail else-
where and it has been proven to be capable of predict-
ing HbA1c levels in nondiabetic individuals [7,12]. In
one of these reports [12], an analytical solution of the
model was presented under an assumption of a constant
glycemia throughout the entire life span of erythrocytes
(HbA1c is NGSP-aligned and LS stands for the life span
of erythrocytes in the equation below):
HbA1c %ð Þ ¼ 91:5 1− 1−e
−kLSMBG
k  LS MBG
 
þ 2:15
This equation was used to calculate values of k for all
the study participants, based on their individual MBG
values, and to compare them with values of k estimated
numerically, based on extrapolated continuous glycemia
courses obtained using the WW and ID methods.
The most important simplification of the model was
related to the assumed constant life span of erythrocytes
equal to 120 days. To show an influence of this assump-
tion on the estimated values of k we also identified the
model (i.e., estimated values of k for all the study partici-
pants) for alternative values of the life span equal to 60,
80, 100, 140 and 160 days.
Assessment of the model performance based on
in vitro data
It was assumed that hemoglobin glycation obeys the same
kinetics in vivo as it does in vitro [6]. The models with k
individualized for each subject were used to predict HbA1c
changes assuming 4 different mechanisms of erythrocyteapoptosis during the in vitro cultivation: the chronological
loss of cohorts, the uniform loss of erythrocytes from all
cohorts, the combination of these two mechanisms, or the
counter-chronological loss of erythrocytes (with the
“youngest” erythrocytes being eliminated first). The per-
centage of the modeled erythrocytes that were left each
day in the simulated cultures reflected the percentage of
the viable erythrocytes measured in the real cultures. No
new erythrocytes were added in the model to reflect the
real-life conditions. A detailed description of the in vitro
modeling was reported earlier [7,12]. The mean difference
(MD) and the mean absolute difference (MAD) of the
measured and the predicted HbA1c levels were used to
assess the model’s performance.
Modeling a relationship of HbA1c and blood
glucose levels
In the second part of the study, the mean k and its inter-
subject variability were estimated for patients with type 1
and type 2 diabetes. The mean k was then used to model
the linear relationship of HbA1c and MBG. The obtained
linear function was compared with the experimental one
that was reported in the ADAG study [2]. However, the
ADAG study reported a regression line with HbA1c as the
independent variable, whereas the model-generated re-
sults should be compared with the line calculated with
MBG as the independent variable (i.e., the one minimizing
the prediction error of HbA1c based on MBG). In both
cases, the correlation coefficient is the same but the slopes
and intercepts of regression lines differ.
We had no access to the raw data from the ADAG
population. Therefore, we used the published summary
statistics of the ADAG study to build a statistical model
of the ADAG population and to draw a sample of 10,000
pairs of HbA1c and MBG from this population with the
Monte Carlo technique using the OpenBUGS 3.2.1 sys-
tem [19]. Based on these simulated data, a regression
line of HbA1c vs. MBG was determined and compared
with the relationship obtained using the HbA1c model.
In the third part of the study, the model with the mean
k was used to simulate the influence of different 120-
day-long glucose profiles on HbA1c, assuming a 120-day
life span of erythrocytes. Additionally, the model with
the mean k value was used to predict steady-state
HbA1c concentrations for constant MBG values in case
of shortening (to 60, 80, and 100 days) and lengthening
(to 140 and 160 days) of the survival of erythrocytes.
Participants
The study group consisted of 30 sequentially enrolled
non-Hispanic white adults including 15 patients with
type 1 diabetes and 15 with type 2 diabetes. Exclusion
criteria were proliferative retinopathy or maculopathy
requiring treatment, renal impairment (creatinine higher
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to NYHA, or cardiac infarction within past 3 months),
and mental impairment.
Baseline characteristics of the study group are presented
in Table 1. All of the subjects had stable metabolic control
prior to the enrollment and a regular lifestyle as confirmed
by the results of an interview. The study adhered to the
Declaration of Helsinki, the subjects provided informed
written consent, and the local ethical committee approved
the study protocol.Statistical analysis
Normality of distribution of all variables was confirmed
using the Shapiro-Wilk W test. Thus, the analysis of vari-
ance (ANOVA) or t-test was applied to analyze the data,
using Statistica ver. 7.1 (StatSoft Inc., Tulsa, OK, USA).
All results are presented as mean ± SD unless other-
wise indicated. A p-value below 0.05 was considered
statistically significant.Results
Mean value and interindividual variability of the overall
glycation rate constant
Table 2 presents the results of in vivo monitoring of the
metabolic control. The mean HbA1c was higher by 0.7%
(7.4 mmol/mol) in patients with type 1 diabetes compared
to those with type 2 diabetes (p = 0.07). This difference
corresponded with a difference of MBG equal to
1.2 mmol/l (p = 0.02) and 1.3 mmol/l (p = 0.02), extrapo-
lated using the WW and ID methods, respectively. The
mean values of the resulting glycemia profiles were not
different, regardless of the extrapolation method that was
used. However, the mean standard deviation was higher
when the ID method was used (p = 0.0000001, 0.000009,Table 1 Baseline characteristics of the study group
Type 1 Type 2 All
n 15 15 30
Sex (% female) 8 (53) 7 (47) 15 (50)
Age (years) 36.4 ± 15.5 57.5 ± 15.8 47.0 ± 18.8
Duration of diabetes (years) 11.8 ± 11.3 10.1 ± 10.7 10.9 ± 10.8
BMI (kg/m2) 23.9 ± 5.6 29.1 ± 5.9 26.5 ± 6.2
C-peptide (nmol/l) 0.11 ± 0.17 1.10 ± 0.63 0.61 ± 0.68
Hemoglobin (g/l) 141 ± 11 139 ± 9 140 ± 10
Hematocrit (%) 41.1 ± 3.1 41.1 ± 2.7 41.1 ± 2.8
RBC (× 1012/l) 4.74 ± 0.38 4.65 ± 0.33 4.69 ± 0.35
WBC (× 109/l) 6.78 ± 1.75 7.40 ± 1.78 7.09 ± 1.76
Fe (μmol/l) 17.9 ± 8.6 16.6 ± 3.8 17.2 ± 6.6
Creatinine (μmol/l) 76 ± 27 68 ± 14 72 ± 22
Data are mean ± SD.
BMI, body mass index; RBC, erythrocyte count; WBC, leukocyte count.and 0.0000001 in patients with type 1 and type 2 diabetes
and in the whole study group, respectively).
Table 3 shows a summary of statistics of values of k
estimated individually for each study participant based
on her or his 120-day-long glucose profile extrapolated
using the WW and ID methods, as well as values of k
calculated using an analytical solution of the model
assuming a constant glycemia in the full 120-day period.
In spite of differences in the glycemic variability, values of
k estimated using both extrapolation methods and those
calculated analytically were almost identical (p = 0.98),
regardless of the type of diabetes (p = 0.82), as revealed by
ANOVA. The k values calculated analytically based on the
constant MBG were higher than those iterated using the
WW glucose data in 25 out of 30 patients (p = 0.006).
However, the mean relative absolute differences were as
little as 0.7% ±0.6% and 1.3% ±1.2% and 1.0% ±1.0% in
patients with type1 diabetes, patients with type 2 diabetes,
and in the whole study group, respectively. In the case of
k values estimated according to the WW and ID
methods, these differences were equal to 0.7% ±1.0%
and 1.7% ± 2.1% and 1.2% ±1.7%. Because of the ab-
sence of considerable differences in the average values
of k estimated using three methods, the values of k esti-
mated on the basis of the WW method are reported in
the remaining part of this work.
Figure 1 demonstrates the mean values ± SD of k
estimated for the life span of erythrocytes ranging from 60
to 160 days. This figure shows that the shorter life span of
erythrocytes is assumed to be, the higher the glycation rate
must be to adjust the model to the glucose and HbA1c
measured in the study participants.
In spite of better metabolic control in patients with
type 2 diabetes, the mean k values were identical in type
1 and type 2 patients (p = 0.96). The variance of k repre-
senting the intersubject variability was similar in both
subgroups (p = 0.45). The coefficient of variation (CV)
of k in patients with type 1 diabetes was equal to 16.7%,
in those with type 2 diabetes, 17.2%; and in the whole
study group, 16.7%.
Measured and predicted HbA1c concentration in vitro
Figures 2 and 3 present the measured HbA1c and mean
courses of the predicted HbA1c during cultivation of the
erythrocytes of patients with type 1 and type 2 diabetes, re-
spectively. Figures 2 and 3 indicates that HbA1c is strongly
overestimated when the assumption that erythrocytes are
removed counter-chronologically is made.
Overestimation of the real HbA1c concentrations
under this assumption can be explained in the following
way. At the beginning of culturing of the erythrocytes,
there is a mixture of erythrocytes in the culture aged
from 0 to 119 days. The in vitro simulation starts with
the calculated HbA1c levels existing in each equal-aged
Table 2 Results of in vivo monitoring of the metabolic control
Type 1 diabetes Type 2 diabetes All participants
HbA1c (%) 7.3 ± 1.1 (5.3, 9.2) 6.6 ± 0.8 (5.3, 8.4) 7.0 ± 1.0 (5.3, 9.2)
HbA1c (mmol/mol) 57 ± 13 (34, 77) 49 ± 9 (34, 68) 52 ± 11 (34, 77)
Period covered with CGM sensors (days) 17.4 ± 4.3 (10.2, 29.6) 16.2 ± 2.2 (10.6, 18.9) 16.8 ± 3.4 (10.2, 29.6)
Time gap between sensor 1 and 2 (days) 26.6 ± 5.9 (18, 43) 29.3 ± 9.2 (19, 50) 28.0 ± 7.7 (18, 50)
Time gap between sensor 2 and 3 (days) 15.7 ± 6.2 (6, 29) 13.8 ± 8.1 (4, 29) 14.7 ± 7.1 (4, 29)
MBG according to WW method (mmol/l) 8.7 ± 1.6 (6.5, 12.4) 7.5 ± 1.0 (6.1, 9.5) 8.1 ± 1.5 (6.1, 12.4)
MBG according to ID method (mmol/l) 8.7 ± 1.6 (6.4, 12.6) 7.5 ± 1.0(6.1, 9.3) 8.1 ± 1.5 (6.1, 12.6)
SD of BG according to WW method (mmol/l) 1.1 ± 0.3 (0.6, 1.4) 1.2 ± 0.7 (0.3, 3.2) 1.2 ± 0.6 (0.3, 3.2)
SD of BG according to ID method (mmol/l) 2.9 ± 0.7 (1.5, 3.9) 2.1 ± 1.0 (1.1, 4.3) 2.5 ± 0.9 (1.1, 4.3)
Data are mean ± SD (range).
HbA1c, hemoglobin A1c concentration; CGM, continuous glucose monitoring; MBG, mean blood glucose concentration; SD, standard deviation; BG, blood glucose
concentration; WW method, 120-day glycemia was extrapolated based on two daily profiles for working days and for weekend obtained using the point-wise
averaging; ID method, 120-day glycemia was extrapolated based on the glucose data with no averaging.
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toring in vivo. This means that the content of HbA1c in
erythrocytes aged 0 days is almost zero while the content
of HbA1c in erythrocytes aged 119 days is almost two
times higher (in the case of a stable mean glycemia
in vivo) than the average content, which is equal to the
measured HbA1c.
During culturing of erythrocytes in vitro, there are two
processes that can change the average HbA1c: hemoglobin
glycation and the removal of nonviable erythrocytes. The
first of these processes leads to an increase in the amount
of the HbA1c in each viable erythrocyte remaining in the
culture. If it were the only process, then the average HbA1c
in vitro would always increase with time. However, the sec-
ond process may lead to an increase, to stabilization, or to
a decrease in the average HbA1c, depending on the way in
which erythrocytes are eliminated from the culture. If
erythrocytes are eliminated in the counter-chronological
way, then, in general, the content of HbA1c in erythrocytes
being removed is lower than the average content of HbA1c
in erythrocytes remaining in the culture, which leads to anTable 3 Results of estimation of the overall hemoglobin glyca
Type 1 diabet
× 10−9 (l mmo
k based on BG according to WW method 1.294 ± 0.216 (0
k based on BG according to ID method 1.292 ± 0.222 (0
k calculated analytically based on MBG 1.300 ± 0.218 (0
Difference of k based on ID and WW methods −0.002 ± 0.015
Difference of k calculated analytically and the one
estimated using WW method
0.006 ± 0.010 (−
Difference of k calculated analytically and the one
estimated using ID method
0.008 ± 0.013 (−
Data are mean ± SD (range).
k, overall hemoglobin glycation rate constant; BG, blood glucose concentration; WW
working days and for weekend obtained using the point-wise averaging; ID method
averaging; MBG, mean blood glucose concentration.increase in the average HbA1c. Therefore, under the as-
sumption of the counter-chronological removal of erythro-
cytes, both above-mentioned processes work together to
increase the average HbA1c. This assumption seems to be
the least realistic because it implies that the oldest erythro-
cytes can live in vitro longer than in vivo. That counter-
chronological removal of erythrocytes is not realistic is
confirmed by the fact that the simulated courses of HbA1c
under this assumption are the most different from the real
measured courses of HbA1c changes.
It is also noteworthy that differences between the sim-
ulated HbA1c concentrations on each particular day for
cultures with different glucose concentrations in the case
of the counter-chronological removal of the erythrocytes
are similar (or even higher) than in the case of the mea-
sured differences. For example, in patients with type 1
diabetes, on the 14th day of culturing, differences for the
simulated HbA1c concentration are equal to 0.61% between
cultures containing 5.2 and 10.5 mmol/l of glucose, and
are equal to 0.58% between cultures containing 10.5 and
15.7 mmol/l of glucose. In comparison, for the measuredtion rate constant (k)
es Type 2 diabetes All participants
l−1 s−1)
.964, 1.794) 1.298 ± 0.223 (1.016, 1.798) 1.296 ± 0.216 (0.964, 1.798)
.965, 1.794) 1.307 ± 0.220 (1.008, 1.787) 1.300 ± 0.217 (0.965, 1.794)
.977, 1.799) 1.313 ± 0.224 (1.024, 1.798) 1.306 ± 0.217 (0.977, 1.799)
(−0.037, 0.035) 0.009 ± 0.031 (−0.033, 0.102) 0.003 ± 0.025 (−0.037, 0.102)
0.009, 0.028) 0.014 ± 0.017 (−0.013, 0.050) 0.010 ± 0.014 (−0.013, 0.050)
0.010, 0.036) 0.005 ± 0.033 (−0.100, 0.040) 0.007 ± 0.025 (−0.100, 0.040)
method, 120-day glycemia was extrapolated based on two daily profiles for




















Life span of erythrocytes (days)
Figure 1 The overall glycation rate constant (k) estimated for different life spans of erythrocytes. The mean ± SD of k is presented for the
life span of erythrocytes ranging from 60 to 160 days.
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0.25%.
A chronological or uniform elimination of erythrocytes
leads to more accurate predictions. The best predictions
are obtained assuming the combined loss of erythrocytes
containing chronological and uniform components
(Table 4). In the whole study group, MDs were simi-
lar in cultures with different glucose concentrations
(p = 0.29), whereas MADs tended to increase with
an increase of glucose level in the culturing medium
(p = 0.0000001). However, both indices were very
small, demonstrating that the combined apoptosis
made it possible to equalize the measured and the
predicted mean HbA1c concentrations.
Linear relationship of HbA1c and MBG
The linear relationship of MBG as a function of HbA1c
reported in the ADAG study was as follows [2]:
MBG mmol=lð Þ ¼ 1:5944HbA1c %ð Þ– 2:5944
We obtained almost the same parameters of the
regression line using the simulated ADAG population:
MBG mmol=lð Þ ¼ 1:589 HbA1c %ð Þ– 2:559
This equation corresponds to the following relation-
ship when MBG is considered the independent variable:
HbA1c %ð Þ ¼ 0:5319MBG mmol=lð Þ þ 2:419
The relationship obtained using the model was as
follows:
HbA1c %ð Þ ¼ 0:5547MBG mmol=lð Þ þ 2:4624
Figure 4 presents a comparison of the last two linear
functions. The model overestimates HbA1c for the
given MBG. However, the mean difference over all
10,000 simulated cases is as little as 0.23% ±0.05%(2.5 ± 0.5 mmol/mol). In the range of MBG from 4 to
20 mmol/l, the mean difference of HbA1c estimates is
equal to 0.33% (3.6 mmol/mol).Changes in HbA1c level in response to different simulated
glycemic profiles
Figure 5A–C show simulations of different glycemia
profiles and their influence on HbA1c level. Figure 5A
presents HbA1c changes in response to the step improve-
ment of the glycemia depending on the magnitude of
improvement (6 hyperglycemia levels are simulated that
drop to the normoglycemia of 5.6 mmol/l) and the dur-
ation of this improvement preceding HbA1c test execu-
tion. Similarly, Figure 5B shows HbA1c in response to
the step deterioration of the glycemia. Based on these
figures it can be observed, for example, that 60 days
after a drop of BG from 22.2 mmol/l to 5.6 mmol/l,
HbA1c is equal to 7.9% (62 mmol/mol), whereas 60 days
after a rise in BG from 5.6 mmol/l to 22.2 mmol/l,
HbA1c is equal to 12.5% (113 mmol/mol), despite the
same average 120-day glycemia in both cases. Using
Figure 5A, based on two HbA1c tests equal to 9.9%
(85 mmol/mol) and 7.5% (58 mmol/mol) performed
30 days one after another and knowing that MBG was
equal to 5.6 mmol/l in both cases, one can predict that
the patient experienced a sudden drop of glycemia
from 19.4 mmol/l about 30 days before the first HbA1c
test was executed.
Figure 5C illustrates the reaction of HbA1c to the tem-
poral (rectangular shape) deterioration of BG lasting for
30 days, depending on the magnitude of this deterioration
and a time period between the end of the hyperglycemia
and execution of the HbA1c test. For example, in the case
of the glycemia deterioration from 5.6 to 22.2 mmol/l last-
ing for 30 days, HbA1c varies from 9.7% (82.6 mmol/mol)































































































Figure 2 The measured and the predicted HbA1c during in vitro cultivation of erythrocytes from patients with type 1 diabetes.
The measured (mean ± SD) HbA1c levels are shown as white circles with error bars and the mean predicted HbA1c levels are shown as: dash-dot
lines, dashed line, dotted line and solid line for the counter-chronological, the uniform, the chronological and the combined (i.e. containing the
chronological and the uniform component) loss of erythrocytes from the culturing medium, respectively. Glucose concentration is equal to:
(A) 5.2 mmol/l; (B) 10.5 mmol/l; (C) 15.7 mmol/l.
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HbA1c test execution.
Figure 6 demonstrates changes of HbA1c in response to
the ramp improvement and the ramp deterioration of the
glycemia lasting for 120 days, depending on the slope of
the ramp. For example, for the linear improvement of the
glycemia from 22.2 mmol/l to 5.6 mmol/l, HbA1c concen-
tration is equal to 8.7% (71 mmol/mol) and for thedeterioration – it is equal to 11.8% (105 mmol/mol). The
MBG concentration is the same in both cases, as it was in
the examples illustrated in Figures 5A and B.
It should be mentioned that if we assumed an erythro-
cyte life span different than 120 days, then the HbA1c
courses presented in Figures 5A-C would have the same
shapes but the time scale would be different. For example,






























































































Figure 3 The measured and the predicted HbA1c during in vitro cultivation of erythrocytes from patients with type 2 diabetes.
The measured (mean ± SD) HbA1c levels are shown as white circles with error bars and the mean predicted HbA1c levels are shown as: dash-dot
lines, dashed line, dotted line and solid line for the counter-chronological, the uniform, the chronological and the combined (i.e. containing the
chronological and the uniform component) loss of erythrocytes from the culturing medium, respectively. Glucose concentration is equal to:
(A) 5.2 mmol/l; (B) 10.5 mmol/l; (C) 15.7 mmol/l.
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would be achieved after 100 days, not 120 days.
Figure 7 illustrates an effect of shortening or lengthen-
ing of the life span of erythrocytes on HbA1c in a patient
having the glycation rate constant equal to the mean value
estimated in 30 study participants for the life span of
120 days. Such a shortened life span occurs, for example,in hemolytic or sickle cell anemia and the lengthened life
span can be observed in thalassemia.
The last simulation assessed whether HbA1c concentra-
tion was a sensitive indicator of hypoglycemia or, in gen-
eral, of short-term glucose variability. For this purpose
two daily glucose profiles were prepared using AIDA [20],
a model-based online simulator of a patient with type 1
Table 4 Mean difference and mean absolute difference of HbA1c measured during the in vitro experiments and
predicted by the model
Glucose concentration Type 1 diabetes Type 2 diabetes All participants
(mmol/l) Mean difference (%)*
5.2 −0.07 ± 0.09 −0.13 ± 0.10 −0.10 ± 0.09
10.5 −0.05 ± 0.08 −0.07 ± 0.08 −0.06 ± 0.07
15.7 −0.00 ± 0.09 −0.13 ± 0.11 −0.06 ± 0.09
Mean absolute difference (%)*
5.2 0.15 ± 0.09 0.19 ± 0.08 0.17 ± 0.08
10.5 0.15 ± 0.05 0.22 ± 0.10 0.18 ± 0.06
15.7 0.32 ± 0.06 0.28 ± 0.10 0.30 ± 0.07
Data are mean ± SD.
*Mean difference and mean absolute difference in (mmol/mol) can be obtained by multiplying values in (%) by 10.93.
The presented parameters were calculated under the assumption that erythrocytes were eliminated from cultures in combination of the chronological and
uniform modes.
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http://www.translational-medicine.com/content/12/1/328diabetes. One of these profiles includes an episode of se-
vere hypoglycemia (Figure 8A). Both profiles were applied
to compose 120-day glycemia courses with variable fre-
quency of the daily hypoglycemic profiles (from “none” to
“everyday”), which were used to model HbA1c. As shown
Figure 8B, for a patient with a mean value of k, HbA1c is
equal to 6.4% (46 mmol/mol) when no hypoglycemia
occurs, and it is equal to 5.8% (40 mmol/mol) when
hypoglycemia episodes occur every day. We calculated
that there is still a 29% chance that the HbA1c level is
higher in a patient experiencing hypoglycemia every day
than in a patient who does not experience hypoglycemia


















Figure 4 Relationship of HbA1c and the mean blood glucose level. Re
glucose (MBG) obtained basing on 10,000 samples (the first exemplary 500
ADAG study population [2] (HbA1c(%) = 0.5319 × MBG(mmol/L) + 2.419) in co
MBG and corresponding HbA1c values (white circles) simulated using the m
constant (k) of 1.296 × 10−9 l mmol−1 s−1 and a constant life span of erythr
dotted lines were calculated using the model with k at the boundaries of aDiscussion
The mean overall glycation rate constant values identified
using 120-day glycemia courses that were extrapolated
based on the CGM data in patients with type 1 and type 2
diabetes support the notion of the same mean rate of
hemoglobin glycation in these two groups of diabetic pa-
tients. The mean k reported in this study is just 3.1%
higher than the mean k obtained in 10 healthy volunteers,
estimated earlier using the same methodology [12], and
2.0% higher than the one that we calculated based on the
results of the 3-month CGM data for 22 patients with dia-
betes and for 3 nondiabetic subjects presented by Nathan
et al. [21]. The mean k reported here is also in a good






















gression line (dashed line) of HbA1c as a function of the mean blood
sampled data points are shown as black diamonds) drawn from the
mparison with the linear regression obtained based on 25 pairs of
odel of hemoglobin glycation, assuming the overall glycation rate
ocytes of 120 days (HbA1c(%) = 0.5547 × MBG(mmol/L) + 2.4624). The




































































































Figure 5 Changes of HbA1c level in response to different simulated glycemic profiles. (A) HbA1c in response to a step improvement of
glycemia to 5.6 mmol/l in day zero; (B) HbA1c in response to a step deterioration of glycemia from 5.6 mmol/l in day zero, (C) HbA1c in response
to hyperglycemia lasting for 30 days that ends in day zero (before day −30 and after day zero the glucose level is equal to 5.6 mmol/l). The
following hyperglycemia levels were used: 8.3 mmol/l (white circles), 11.1 mmol/l (white triangles), 13.9 mmol/l (white squares), 16.7 mmol/l
(white diamonds), 19.4 mmol/l (black circles) and 22.2 mmol/l (black triangles). For two utmost lines error bars were calculated using the model
with k at the boundaries of a 95% confidence interval (i.e. mean k ±1.96 × SD).
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http://www.translational-medicine.com/content/12/1/328the basis of a limited number of samples utilizing in vivo
or in vitro experiments, when methodological differences
are accounted for [3,4,6,7,18].
The mean k values were only marginally different for
three methods of the long-term glycemia extrapolation
that were used. This result confirms the data reported in
the clinical studies showing that HbA1c is sensitive toMBG level but not to glycemic short-term variations
[2,21-23] because the MBG levels used in these three
methods were very similar to each other, whereas the
glucose variability measures were significantly different.
The life span of erythrocytes shorter or longer than
the assumed 120-day would not change the conclusion
































Initial (circles) / final (triangles) glycemia
Figure 6 HbA1c in response to a ramp improvement (circles) and ramp deterioration (triangles) of glycemia. The improvement or
deterioration of glycemia last for 120-day. In case of the improvement the initial glycemia is equal to: 8.3 mmol/l (white circles), 11.1 mmol/l
(white triangles), 13.9 mmol/l (white squares), 16.7 mmol/l (white diamonds), 19.4 mmol/l (black circles) and 22.2 mmol/l (black triangles). The
same hyperglycemic levels are used as the final glycemia in case of the ramp of deterioration of the glycemic control. In case of the improvement
final glycemia is equal to 5.6 mmol/l and in case of the deterioration the initial glycemia is equal to 5.6 mmol/l. For two utmost lines error bars
were calculated using the model with k at the boundaries of a 95% confidence interval (i.e. mean k ±1.96 × SD).
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http://www.translational-medicine.com/content/12/1/328type 2 diabetes, provided that the mean erythrocyte sur-
vival was similar in these two groups. However, the
mean value of k would be affected if the erythrocyte life
span was different than 120 days.
The interindividual CV of k was similar regardless of
the type of diabetes, but it was higher than the value re-
ported earlier in healthy volunteers [12] (p = 0.025). The
obtained CV is high, but it cannot be automatically at-
tributed in full to variability of glycation rate. Ladyzynski
et al. [12] demonstrated that a major part of variability of
k in healthy volunteers could be explained by random er-
rors of HbA1c and glycemia measurements and, more im-
portantly, by a heterogeneity of erythrocyte life span [12].
Furne et al. [24] estimated that by using the end-
alveolar carbon monoxide technique, the standard devi-
ation of the life span of erythrocytes in healthy subjects














Figure 7 HbA1c in response to constant MBG maintained during the w
equal to 1.296 × 10−9 l mmol−1 s−1 was applied and the following life span
(white triangles), 100 days (white squares),120 days (white diamonds), 140
error bars were calculated using the model with k at the boundaries of a 9explain the variability of k obtained in the current study
and to justify the resulting differences in HbA1c corre-
sponding to a given glucose concentration, which can be
observed in Figure 4, where, for example, at an MBG
equal to 15.5 mmol/l, HbA1c varies from 8.3% (68 mmol/
mol) to 13.8% (127 mmol/mol). Higher CV of k noted in
our study in comparison with the study concerning
healthy volunteers [12] suggests that the heterogeneity of
the life span of the erythrocytes might be higher in pa-
tients with diabetes. This is in line with the results
reported by Virtue et al. [25], who demonstrated that in a
group of patients with type 2 diabetes, this parameter was
equal to 25 days.
Higher CV noted in our study suggests that the other
above-mentioned sources of variability might also be
more pronounced or that k is more significantly influ-

















hole life span of erythrocytes. In each simulation the model with k
s of erythrocytes were used: 60 days (white circles), 80 days
days (black circles), 160 days (black triangles). For two utmost lines

















































Number of hypoglycemic episodes (days with hypo / days)
A 
B 
Figure 8 Changes of HbA1c level in response to hypoglycemia. (A) two daily glucose profiles without (dotted line) and with (solid line) an
episode of hypoglycemia that were used to compose 120-day glycemia courses with different frequency of hypoglycemic episodes; (B) HbA1c in
response to 120-day glycemia courses composed of daily profiles shown in panel (A) containing the hypoglycemic profile with the following
frequencies: never (0), weekly (1/7), every third day (1/3), every second day (1/2), everyday (1/1).
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studies are required to confirm this hypothesis. Never-
theless, the model also can be individualized, applying
the method used in this study, to fit a particular patient’s
data more precisely.
The HbA1c model with k individually identified for each
patient was used to predict HbA1c in cultures of patients’
erythrocytes. We tested a few possible modes of erythro-
cyte removal, because of a lack of any method that could
actually measure which erythrocytes are lost. The results
indicated a high ability of the model to predict HbA1c
when two modes of erythrocyte removal – chronological
loss and uniform loss – were combined. The results of
in vitro studies strengthen the validity of the model under
in vivo conditions, because both models share the same
k for a particular subject and the in vitro simulation
starts with the calculated HbA1c levels in each equal-
aged cohort of erythrocytes on the last day of theglucose monitoring in vivo. This means that the two
models are strongly interrelated [7].
The average linear relationship of HbA1c as a function
of MBG, which was modeled using the mean k and a
constant 120-day life span of erythrocytes, reproduced
the relationship of these variables obtained using the
data sampled from the ADAG population despite differ-
ences between the groups (e.g., in terms of ethnicity,
proportion of nondiabetic individuals and patients with
type 1 and type 2 diabetes). This is yet another confirm-
ation of the validity of the model.
More importantly, the fact that both linear relationships
are almost identical has significant implications regarding
the glycation rate, the life span of erythrocytes, and the
glycemic control. On the one hand, if the life span of
erythrocytes shortens with a worsening of glycemic con-
trol, as was suggested in a few reports [25,27], then the
mean k must increase to compensate for the shorter time
Ladyzynski et al. Journal of Translational Medicine 2014, 12:328 Page 14 of 16
http://www.translational-medicine.com/content/12/1/328of glycation (otherwise the slopes of both lines would have
to be different). Possible mechanisms responsible for such
an increase include patients’ susceptibility to oxidative
stress and an association of hyperglycemia with free-
radical-mediated lipid peroxidation [26] or the existence
of high and low hemoglobin glycation phenotypes [28,29].
On the other hand, some studies have indicated that the
life span of erythrocytes is independent of glycemic control
or even that it is longer in patients with poorer control
[18,30,31], implying that the mean glycation rate is not cor-
related or that it is negatively correlated with glycemic
control.
Unfortunately, based solely on the hemoglobin glyca-
tion model, it is not possible to judge, whether the life
span of erythrocytes and the glycation rate constant are
negatively, positively, or not correlated with HbA1c. This
is related to the fact that in the model the glycation rate
constant k and the life span of erythrocytes are not
present separately but as a product of these two vari-
ables (see, above, the second equation in section Estima-
tion of the overall glycation rate constant). Therefore, it
is not possible to reach a conclusion about possible
changes of one of these parameters as a function of
HbA1c without having prior knowledge about changes of
the other parameter. A reliable method of measuring the
survival of erythrocytes in vivo is required to solve this
problem. In the absence of such a method, mathematical
modeling can be used to incorporate a description of the
aging of erythrocytes into the glycation model [32].
From a practical point of view, the most important
conclusion, that can be drawn from a good agreement of
both linear relationships considered above, is that changes
in the life span must be balanced by changes in the glyca-
tion rate across the wide range of HbA1c levels to ensure
nearly a constant product of these two variables; otherwise
it would not be possible to reproduce the average relation-
ship of HbA1c and MBG obtained in the ADAG study
using the model with k equal to 1.296 × 10−9 l mmol−1 s−1
and the 120-day life span of erythrocytes. In fact, the same
result would be achieved even if some other value of the life
span of erythrocytes were assumed. This is related to the
fact that k is estimated from the model based on the
assumed life span of erythrocytes, that is, the shorter the life
span, the higher the estimated value of k and vice versa.
Because of a good agreement of the simulated and the
experimental relationship of HbA1c and MBG obtained
using the mean k and the same mean life span of eryth-
rocytes, the same values of these parameters can be used
to obtain reliable predictions of HbA1c in response to
different glycemic profiles in the average patient with
diabetes. We conducted a few series of such predictions
for different glycemic profiles preceding the HbA1c test
execution. The conclusions from these predictions are as
follows: (1) interpreting HbA1c as a measure of MBG ismeaningful only in the case of stable glycemic control;
(2) the HbA1c level might vary widely during sudden
changes in glycemia, even in the case of glycemia pro-
files with the same MBG level; (3) HbA1c is not a sensi-
tive indicator of short-term glycemic variability; and (4)
there is a considerable ambiguity in interpreting the
result of a single HbA1c measurement when no additional
information about the patient is available (e.g., previous
HbA1c or BG values).
These conclusions are in good agreement with obser-
vations known from clinical practice and demonstrated
in clinical trials. However, using the model it is possible
to assess what quantitative statements (for example,
“HbA1c is not a sensitive indicator of the short-term
glycemic variability”) really mean in terms of concrete
numerical values of HbA1c and BG.
From a practical standpoint, the most important value
of the presented work is that having a positively verified
model, in which k can be identified for a particular pa-
tient, and taking into consideration the relative mathemat-
ical simplicity of the model, more frequent tests of HbA1c
might be used together with the results of modeling to
decrease ambiguity of interpreting HbA1c in terms of gly-
cemic control. For example, one can calculate monthly
estimates of MBG using the model and monthly HbA1c
tests instead of assuming that BG was constant for the
whole life span of erythrocytes. In other words, the model
make it possible to improve interpretability of the most
recent HbA1c value by combining all the evidence avail-
able within 3–4 months related to glycemia monitoring
and HbA1c testing.
Conclusions
Our results support the notion that patients with type 1
and type 2 diabetes are characterized by the same mean
value of the overall glycation rate constant. There is no
significant difference between the mean value of this para-
meter in patients with diabetes and in healthy individuals.
The obtained results suggest that reciprocal changes in
glycation rate and the life span of erythrocytes exist in a
wide range of HbA1c values. Thus, for an average patient
with either type 1 or type 2 diabetes, no modifications of
parameters of the hemoglobin glycation model are re-
quired to obtain meaningful HbA1c predictions. Such a
model can be used to simulate the influence of different
glycemia courses on HbA1c level, making it possible to
go beyond the averaged linear relationship of HbA1c and
the mean glucose level over the whole life span of eryth-
rocytes. Simulation experiments that were conducted
confirm observations known from the clinical practice
(i.e., that interpretation of HbA1c as a measure of MBG
is fully justified only in the case of the stable glycemic
control and that HbA1c is not a sensitive indicator of
short-term glycemic variability).
Ladyzynski et al. Journal of Translational Medicine 2014, 12:328 Page 15 of 16
http://www.translational-medicine.com/content/12/1/328There is considerable intersubject variation in the rela-
tionship of HbA1c and the mean blood glucose level. Based
on evidence from the literature, the variation is more likely
related to the heterogeneity of the life span of erythrocytes
than to variability of the glycation rate constant, but further
studies are required to confirm this hypothesis. Neverthe-
less, the model can be individualized to fit a particular sub-
ject’s data by applying the method used in our study. The
model and more frequent tests of HbA1c might be
used to decrease ambiguity of interpreting HbA1c in
terms of glycemic control.
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